Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
The upcoming cancer meeting shows Roche and Bristol trying to catch up with Merck & Co, with some read-across to biotech.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.